If the FDA isn’t regulating every aspect of AI in healthcare who will? Executives debate at San Diego waterfront

A pivotal debate is unfolding at the BIO International Convention 2026 in San Diego this week, as healthcare and technology executives grapple with a critical question: if the U.S. Food and Drug Administration (FDA) doesn't regulate every facet of Artificial Intelligence in healthcare, who will? The urgent discussion comes as the FDA has just released updated guidance on AI-enabled medical devices in June 2026, signaling a significant shift in its regulatory approach amid rapid AI advancement. The stakes are incredibly high, with the FDA latest framework demanding more stringent requirements around data provenance, algorithm transparency, and predetermined change control plans (PCCPs) for AI-powered medical devices. This proactive stance aims to manage the 'black box' problem and algorithmic drift inherent in Machine Learning, ensuring patient safety and device efficacy throughout their total product lifecycle. However, the conversation extends beyond federal oversight, with states like California already implementing their own AI laws, affecting San Diego's burgeoning life sciences sector by addressing patient disclosure and clinical communication oversight, revealing a patchwork of regulations taking shape. As the public comment period for some of the FDA new draft guidances closes in early August 2026, the outcomes of these intense debates at BIO International will undoubtedly shape future policy and industry compliance. Companies must now navigate a complex, multi-layered regulatory environment, from federal mandates to state-specific requirements, while the World Health Organization (WHO) also pushes for global harmonization, underscoring the pressing need for clear, coordinated governance in the swiftly evolving landscape of AI in healthcare.